Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

With €20.1M funding, Swiss biotech startup iOnctura aims to treat cancer and fibrosis effectively

Editorial team by Editorial team
July 15, 2020
in News, (Crowd)funding, Startups
0
Europe rumoured to get its largest data centre in the Netherlands and Facebook could be behind it
91
SHARES
LinkedInTwitterWhatsAppFacebook

Cancer is one of the most deadly diseases and is estimated to affect one in three people, especially in the western world. WHO (World Health Organisation) claims that there has been a 70% increase in the number of cancer cases across the world with the number continuously on the rise each year. In addition to being deadly, cancer treatment costs a bomb, at least for the common people.

New improvements in cancer treatment

The cellular and micro-environmental processes in chronic fibrosis and cancer are identical. Swiss clinical stage biotechnology company iOnctura is building on this link to develop a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

Founded in 2017 as a spun out from Merck and backed by M Ventures, iOnctura’s programmes harness the combined effect of direct anti-tumour and immune-mediated activity. It intends to deliver molecules with superior safety and clinical efficiency in oncology.

The lead program of iOnctura, IOA-244 entered the clinic in the first quarter of this year. The study intends to clinically demonstrate for the first time that a highly selective PI3Kδ inhibition drives an immune-mediated response and a direct anti-tumoural effect in a stratified patient population across multiple solid tumour indications. The company’s second program is a novel autotaxin (ATX) inhibitor for patients with solid tumours burdened with cancer-associated fibrosis.

Investment to accelerate development of therapies

In a recent development, iOnctura announced that it has raised an additional €5.1 million, which takes the Series A funding round to €20.1 million. The funding round was led by 3B Future Health Fund (formerly) Helsinn Investment Fund S.A. along with SICAR, which joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq.

The Swiss biotech will use the investment to accelerate the development of its next-generation dual immune and tumour targeting therapies. It is expected to bring its ATX-inhibitor with dual utility in organ specific and cancer associated fibrosis into human testing in early 2021. Recently, the company strengthened its team by roping in Dr. Joanna Horobin as Chair.

Catherine Pickering, Chief Executive Officer of iOnctura, said: “I am pleased to welcome 3B Future Health Fund to our strong investor syndicate. This oversubscribed Series A round provides further validation and support of our strategy as we progress our novel, highly selective, PI3Kδ inhibitor and our differentiated ATX inhibitor through clinical development.”

Riccardo Braglia, 3B Future Health Fund Chairman and Helsinn Group Vice Chairman and Chief Executive Officer, commented: “We look to invest in early-stage companies which are developing novel treatments in areas of high unmet patient need. We have been very impressed with the world class team at iOnctura and the potential of its next generation molecules targeting cancer and fibrosis.”

Stock photo from CI Photos/Shutterstock

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Hiring during COVID Intrinsic Search
Hiring SaaS sales executives
Check out the do's and don'ts while hiring SaaS sales executives
Check out the do's and don'ts while hiring SaaS sales executives Show Less
Read more
Tags: fundingstartups
Share6Tweet22SendShare39

Partner content | Work with us

Future of coding: CTOs discuss low-code versus custom code software development for their business

Why now is the perfect time to start hiring for 2021

SaaS sales in 2021: 9 predictions from an industry expert

Diversity in hiring for SaaS: the often overlooked topic of ageism

Boost your scale-up’s growth by outsourcing to these top Eastern European software development companies

Subscribe to our daily newsletter

Check your inbox or spam folder to confirm your subscription.

Breaking news from Amsterdam | Partner

Meet the 10 Dutch scaleups selected by Amsterdam-based Techleap.nl for Rise Programme 2021

Amsterdam-based 3D Hubs acquired by Protolabs for €272.1M; here’s what you need to know

Amsterdam-based INKEF Capital leads €5M Series A funding round of this Dutch startup

4 experts predict what 2021 might hold for the startup ecosystem of Amsterdam

Advertisement

Trending

3D Hubs
Amsterdam

Amsterdam-based 3D Hubs acquired by Protolabs for €272.1M; here’s what you need to know

January 19, 2021
Amsterdam
Amsterdam

9 promising sustainable startups from Amsterdam to watch in 2021

January 20, 2021
BUX
News

The crypto platform of Amsterdam fintech BUX witnesses “explosive growth” as Bitcoin remains popular

January 22, 2021
  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info